Dubbed Omnipod Discover, the system made its debut in multiple international markets earlier this year. Ahead of its full stateside market release, the company said it has already logged 15,000 U.S. users of its Omnipod 5 insulin pump as well as 1,800 healthcare providers as part of an initial rollout.
The platform is now available to all Omnipod 5 wearers, while professionals can enroll and receive training through a company sales representative. Users receive weekly reports through text messages on their smartphone, and providers can use glucose data to suggest adjustments to pump settings and bolus events.
“The future of diabetes care is not just about generating more data, it’s about making that data meaningful,” said Insulet’s chief medical officer, Dr. Trang Ly. “Omnipod Discover simplifies data review for Omnipod 5 users and their healthcare providers so they spend less time gathering information and more time collaborating on diabetes management.”
Related: Insulet launches enhanced Omnipod 5 algorithm, expands Abbott compatibility
In June, Insulet showed that Omnipod Discover could improve a user’s time in a healthy glucose range, with the presentation of real-world data at the American Diabetes Association’s Scientific Sessions in New Orleans. About one-third of self-managed users saw their time-in-range increase by 3% or more.
Omnipod Discover is already available in Australia, Israel, Kuwait, Saudi Arabia, Spain, Qatar and the United Arab Emirates. The company plans to open the platform up to Greece and Croatia in the first half of next year.
Its next-generation, closed-loop pump, the Omnipod 6, is also slated for release in 2027 for people with type 1 and type 2 diabetes.
